Yahoo Web Search

Search results

1. • 

     This 6% Yielding Dividend Stock Could Pump Up Your Passive-Income Stream

     Motley Fool via Yahoo Finance· 6 days ago

     Pfizer's a good dividend stock to buy because its rate of new product launches is outpacing the...

2. • 

     Is Bristol Myers' Dividend in Danger?

     The Motley Fool via AOL· 4 days ago

     Rising costs and minimal growth pose a problem for Bristol Myers as many of the drugmaker's top drugs, including Eliquis, Revlimid, and Opdivo, are...

3. • 

     Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?

     Investor's Business Daily· 21 hours ago

     Last year, sales tumbled 42% to nearly $58.5 billion. Top sellers included Comirnaty and Paxlovid,...

4. • 

     Big Pharma layoffs continue, as Bristol-Myers Squibb cuts 2,200 jobs, $1.5B in costs

     BenefitsPRO· 5 days ago

     Bristol-Myers Squibb has announced that it plans to cut $1.5 billion in expenses by the end of 2025,...

5. • 

     Decoding Pfizer Inc (PFE): A Strategic SWOT Insight

     GuruFocus.com via Yahoo Finance· 5 days ago

     The company's commitment to research and development is evident in its sustained investment, with $2,493 million allocated in the first quarter of 2024....

6. • 

     Down but Not Out: 3 Stocks to Buy on a Post-Earnings Dip

     Motley Fool via Yahoo Finance· 3 days ago

     As if that earnings miss weren't enough, the company faces a patent cliff, with Eliquis and Opdivo...

7. • 

     Imbruvica interactions: Alcohol, supplements, and more

     Medical News Today· 2 days ago

     Imbruvica (ibrutinib) is a brand-name drug that’s prescribed for certain blood cell problems,...

8. • 

     Pfizer's next move: Can it break above $30? | Invezz

     Invezz· 2 days ago

     Pfizer Inc. (NYSE:PFE) faced a challenging 2023 in the stock market, with its shares plummeting from over $50 to a low of $25. On May 1, 2024, Pfizer...

9. • 

     Blockbuster Drug Patent Thickets Signal 'Strategic Behavior'

     MedPage Today· 2 days ago

     An analysis of patent applications for 10 top-selling prescription drugs found that nearly...

10. • Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3...

      Morningstar· 7 days ago

      FN Media Group News Commentary - There is much activity in finding better ways in mitigating muscle loss for the cancer patients… many clinical studies are looking for elite performance nutritional ...